Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients or their health care proxies must be able to provide consent to participate in this trial.~* Patients must have one of the following diagnoses which has not responded or recurred following at least one prior chemotherapy regimen or radiation therapy:~  * anaplastic astrocytoma, glioblastoma multiforme or oligodendroglioma~ * primary CNS lymphoma~ * malignant disease metastatic to the CNS~* Patients must be candidates for high dose chemotherapy and autologous stem cell transplant according to the following criteria:~  * Patients must be between the ages of 18 and 70 years (inclusive)~ * Patients must have a left ventricular ejection fraction greater than or equal to 45% by MUGA or echocardiogram~ * Patients must have adequate pulmonary function with FEV1, FVC and DLCO greater than or equal to 50% of predicted~ * Patients must have serum direct bilirubin less than or equal to 2.0 mg/dl and transaminases less than or equal to 3x institutional upper limit of normal~ * Patients must have serum creatinine less than or equal to 2 mg/dl with creatinine clearance greater than or equal to 60 ml/min (either calculated or measured)~ * Patients must have an ECOG performance status between 0 and 2~* Patients must be at least 4 weeks from last cytoreductive chemotherapy.~* Expected survival of at least 3 months~Exclusion Criteria:~* Patients with uncontrolled metastatic disease outside of the CNS which would itself, in the investigator's opinion, limit survival to less than 6 months~* Patients with uncontrolled seizures are ineligible.~* Patients with a history of myocardial infarction within the preceding 6 months, significant arrhythmia within the preceding 3 months, or uncontrolled hypertension or congestive heart failure are ineligible.~* Patients with unstable angina are ineligible.~* Pregnant or lactating women are ineligible.~* Male and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligible.~* Patients with uncontrolled, active infection are ineligible.~* Patients infected with HIV are ineligible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).